Health expert recommends RSV vaccination following the death of a 40-year-old man

Following the death of a 40-year-old man from Respiratory Syncytial Virus (RSV), Professor of Public Health Theodoros Lytras emphasized the availability of protection options. Speaking to RIK on February 11, 2026, Lytras noted that RSV has historically been an underestimated respiratory virus. The virus primarily affects children under the age of two and seniors aged 75 and older. Currently, an RSV vaccine is available for adults between 60 and 74 with underlying conditions and all individuals over 75. Pregnant women are also eligible for the vaccine to provide protection to newborns. Recommendations also include the administration of monoclonal antibodies to infants to prevent severe illness. Although only a small percentage of cases require hospitalization, the symptoms can be severe. These measures aim to mitigate the impact of the virus on high-risk populations. The professor urged the public to utilize the available medical tools to prevent further fatalities.